Raghda Saad Zaghloul Taleb
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Raghda Saad Zaghloul Taleb has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Barbara Sitek
Medizinisches Proteom-Center, Ruhr-Universität Bochum, Bochum, Germany
2 shared publicationsDoreen Younan
Clinical and Chemical Pathology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt
2 shared publicationsMartin Eisenacher
Medizinisches Proteom-Center, Ruhr-Universität Bochum, Bochum, Germany
2 shared publicationsMatthias Tenbusch
Institute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany
2 shared publications- Naylan Fayez Wahba Khalil
Department of Physical Medicine, Rheumatology and Rehabilitation, Faculty of Medicine, Alexandria University, Alexandria Alexandria, Egypt
2 shared publications Pacint Moez
Clinical and Chemical Pathology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt
2 shared publications
Latest Publications
- Open Access
- 8 December 2025
- Published by Springer Nature in Egyptian Rheumatology and Rehabilitation
- Vol. 52 (1) , 71
Serum interleukin-18 as a biomarker of disease activity and interstitial lung disease in rheumatoid arthritis
Background: Rheumatoid arthritis (RA) is a chronic systemic condition, marked by inflammatory alterations of the synovial tissue in joints, cartilage, and bone. Interleukin-18 (IL-18), a member of the IL-1 family, is a significant pro-inflammatory cytokine that could contribute to the development of RA. We aimed to measure the serum IL-18 level in patients with RA and correlate its level with different disease characteristics, disease activity, and the presence of interstitial lung disease. Methods: A case-control study was conducted on 121 subjects: 60 adult RA patients who met the 2010 ACR/EULAR criteria for RA, and 61 age and sex-matched healthy controls. All patients have undergone a comprehensive evaluation, including a history and physical examination, a disease activity score (DAS28), and chest x-ray and high-resolution computed tomography of the chest. Laboratory investigations included C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), rheumatoid factor (RF), anti-citrullinated protein antibodies (ACPA), and serum IL-18 level. Results: The 60 RA patients were 17 males (28.3%) and 43 females (71.7%) with a mean age of 45.13 ± 13.70 years, and disease duration was 8.86 ± 7.91 years. Interstitial lung disease related to RA was found in 8 RA patients (13.3%). The mean serum IL-18 level among RA patients was (652.3 ± 245.2 pg/mL), while in the control group it was (323.1 ± 106.6 pg/mL) with a statistically significant difference ( p < 0.001). Moreover, the mean level of serum IL-18 in RA patients with interstitial lung disease (ILD) was (896.4 ± 162.7 pg/mL), and this was statistically significant when compared to RA patients without ILD ( p = 0.001). There was a significant positive correlation between IL-18 and ESR, CRP, RF, and DAS28 ( p = 0.013, p = 0.010, p < 0.001, and p < 0.001, respectively). Conclusion: Serum IL-18 was significantly higher in RA patients than in controls; furthermore, it was positively correlated with inflammatory markers and disease activity. An increased IL-18 level was associated with the presence of ILD; thus, IL-18 could be a potential biomarker for assessing RA activity and associated ILD.
- 8 December 2025
- Published by Springer Nature in Egyptian Rheumatology and Rehabilitation
- Vol. 52 (1) , 71
Open AccessSerum interleukin-18 as a biomarker of disease activity and interstitial lung disease in rheumatoid arthritis
Background: Rheumatoid arthritis (RA) is a chronic systemic condition, marked by inflammatory alterations of the synovial tissue in joints, cartilage, and bone. Interleukin-18 (IL-18), a member of the IL-1 family, is a significant pro-inflammatory cytokine that could contribute to the development of RA. We aimed to measure the serum IL-18 level in patients with RA and correlate its level with different disease characteristics, disease activity, and the presence of interstitial lung disease. Methods: A case-control study was conducted on 121 subjects: 60 adult RA patients who met the 2010 ACR/EULAR criteria for RA, and 61 age and sex-matched healthy controls. All patients have undergone a comprehensive evaluation, including a history and physical examination, a disease activity score (DAS28), and chest x-ray and high-resolution computed tomography of the chest. Laboratory investigations included C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), rheumatoid factor (RF), anti-citrullinated protein antibodies (ACPA), and serum IL-18 level. Results: The 60 RA patients were 17 males (28.3%) and 43 females (71.7%) with a mean age of 45.13 ± 13.70 years, and disease duration was 8.86 ± 7.91 years. Interstitial lung disease related to RA was found in 8 RA patients (13.3%). The mean serum IL-18 level among RA patients was (652.3 ± 245.2 pg/mL), while in the control group it was (323.1 ± 106.6 pg/mL) with a statistically significant difference ( p < 0.001). Moreover, the mean level of serum IL-18 in RA patients with interstitial lung disease (ILD) was (896.4 ± 162.7 pg/mL), and this was statistically significant when compared to RA patients without ILD ( p = 0.001). There was a significant positive correlation between IL-18 and ESR, CRP, RF, and DAS28 ( p = 0.013, p = 0.010, p < 0.001, and p < 0.001, respectively). Conclusion: Serum IL-18 was significantly higher in RA patients than in controls; furthermore, it was positively correlated with inflammatory markers and disease activity. An increased IL-18 level was associated with the presence of ILD; thus, IL-18 could be a potential biomarker for assessing RA activity and associated ILD.
- 28 May 2025
- Published by Elsevier in Clinical Biochemistry
- Vol. 138, 110954
Circulating plasma RNY1 as a potential biomarker of breast cancer: a case-control study
- 28 May 2025
- Published by Elsevier in Clinical Biochemistry
- Vol. 138, 110954
Circulating plasma RNY1 as a potential biomarker of breast cancer: a case-control study
- Open Access
- 23 September 2024
- Published by Springer Nature in Human Genomics
- Vol. 18 (1) , 1-9
Study of adiponectin gene (rs1501299) polymorphism and serum adiponectin level in patients with primary knee osteoarthritis
Background: We aimed to study, for the first time in the Egyptian population, the relationship between the serum adiponectin level in knee osteoarthritis (KOA) patients and its correlation with clinical, radiological, and ultrasonographic characteristics. Additionally, investigate the relationship between the adiponectin (ADIPOQ) gene rs1501299 (+ 276G/T) polymorphism and KOA susceptibility and severity. Methods: This case-control study enrolled 40 patients with primary KOA and 40 matched controls. All patients underwent physical examination of the knee, pain assessment using the visual analogue scale (VAS), and functional evaluation by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Severity of KOA was assessed by Kellgren Lawrence (KL) grading scale and ultrasonography grading systems. Serum adiponectin levels and adiponectin (ADIPOQ) gene single nucleotide polymorphism (SNP) (rs1501299) genotyping were done for all patients and controls. Results: The study included 40 patients with primary symptomatic KOA and 40 controls with comparable age, sex, and body mass index. The genotype of the rs1501299 (+ 276G/T) polymorphism of the ADIPOQ gene was determined using TaqMan allelic discrimination. An enzyme-linked immunosorbent test was used to measure the level of serum adiponectin. The Western Ontario and McMaster Universities Osteoarthritis (WOMAC) score was used to assess functional capability, while the visual analogue scale was utilised to assess knee pain. Using the Kellgren-Lawrence (KL) grading method and global femoral cartilage (GFC) ultrasound grading, the severity of KOA was assessed. No significant differences between patients and controls as regards the genotype distributions and allele frequencies (p = 0.400, p = 0.507, respectively) of ADIPOQ gene rs1501299 (+ 276G/T) polymorphism. Furthermore, serum adiponectin level was significantly higher in the patients compared to healthy subjects (p < 0.001). Additionally, adiponectin level had a significant negative correlation with disease severity as evaluated by KL and GFC grading (r=-0.351, p = 0.027 and r=-0.397, p = 0.011, respectively). Conclusions: The ADIPOQ gene rs1501299 (+ 276G/T) polymorphism was not associated with KOA severity or vulnerability. The level of adiponectin considerably reduced as the severity of KOA rose, indicating that adiponectin may have a preventive effect in KOA.
- 23 September 2024
- Published by Springer Nature in Human Genomics
- Vol. 18 (1) , 1-9
Open AccessStudy of adiponectin gene (rs1501299) polymorphism and serum adiponectin level in patients with primary knee osteoarthritis
Background: We aimed to study, for the first time in the Egyptian population, the relationship between the serum adiponectin level in knee osteoarthritis (KOA) patients and its correlation with clinical, radiological, and ultrasonographic characteristics. Additionally, investigate the relationship between the adiponectin (ADIPOQ) gene rs1501299 (+ 276G/T) polymorphism and KOA susceptibility and severity. Methods: This case-control study enrolled 40 patients with primary KOA and 40 matched controls. All patients underwent physical examination of the knee, pain assessment using the visual analogue scale (VAS), and functional evaluation by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Severity of KOA was assessed by Kellgren Lawrence (KL) grading scale and ultrasonography grading systems. Serum adiponectin levels and adiponectin (ADIPOQ) gene single nucleotide polymorphism (SNP) (rs1501299) genotyping were done for all patients and controls. Results: The study included 40 patients with primary symptomatic KOA and 40 controls with comparable age, sex, and body mass index. The genotype of the rs1501299 (+ 276G/T) polymorphism of the ADIPOQ gene was determined using TaqMan allelic discrimination. An enzyme-linked immunosorbent test was used to measure the level of serum adiponectin. The Western Ontario and McMaster Universities Osteoarthritis (WOMAC) score was used to assess functional capability, while the visual analogue scale was utilised to assess knee pain. Using the Kellgren-Lawrence (KL) grading method and global femoral cartilage (GFC) ultrasound grading, the severity of KOA was assessed. No significant differences between patients and controls as regards the genotype distributions and allele frequencies (p = 0.400, p = 0.507, respectively) of ADIPOQ gene rs1501299 (+ 276G/T) polymorphism. Furthermore, serum adiponectin level was significantly higher in the patients compared to healthy subjects (p < 0.001). Additionally, adiponectin level had a significant negative correlation with disease severity as evaluated by KL and GFC grading (r=-0.351, p = 0.027 and r=-0.397, p = 0.011, respectively). Conclusions: The ADIPOQ gene rs1501299 (+ 276G/T) polymorphism was not associated with KOA severity or vulnerability. The level of adiponectin considerably reduced as the severity of KOA rose, indicating that adiponectin may have a preventive effect in KOA.
- Open Access
- 14 November 2023
- Published by Springer Nature in BMC Ophthalmology
- Vol. 23 (1) , 1-8
Study of aqueous humour inflammatory mediators’ levels in a cohort of Egyptian patients with diabetic macular oedema
Background: The aim was to study aqueous humour inflammatory mediators’ levels in a cohort of Egyptian patients with diabetic macular oedema (DMO). Methods: This was a case-control prospective study conducted on 2 groups: 25 eyes of 22 (11 females) patients seeking treatment for DMO as patients group, and 10 eyes of 10 (4 females) cataract patients as a control group. Aqueous humour was aspirated before intravitreal injection (patients’ group) or cataract surgery (control group). Inflammatory mediators in aqueous humour were measured using a multiplex bead immunoassay kit of 27 pre-mixed cytokines. Results: Eotaxin, interferon gamma-induced protein 10 (IP-10), monocyte chemoattractant protein-1 (MCP-1/CCL2) and interleukin-8 (IL-8/CXCL8) were found significantly higher in patients’ group compared to control group (p = 0.043, 0.037, 0.001, 0.015 respectively). On the contrary, interferon-gamma (IFN-gamma) and granulocyte colony-stimulating factor (G-CSF) were found significantly higher in control group than patients’ group (p = 0.003, 0.019 respectively). Basic fibroblast growth factor (Basic-FGF/FGF-2) and interleukin-1 receptor antagonist (IL-1ra) were found higher (but not statistically significant) in controls (p = 0.100 and 0.070 respectively). Additionally, a negative and significant correlation was found between Eotaxin level in aqueous humour and central macular thickness. Conclusions: Some mediators might be implicated in the pathogenesis of DMO either augmenting or suppressing role. Eotaxin, IP-10, MCP-1 and IL-8 might have a role in cases not responding to standard anti-vascular endothelial growth factor (VEGF) therapy. IL-1ra might have a protective role; therefore, the effectiveness of intravitreal injection of IL-1ra homologue needs to be studied in future clinical trials.
- 14 November 2023
- Published by Springer Nature in BMC Ophthalmology
- Vol. 23 (1) , 1-8
Open AccessStudy of aqueous humour inflammatory mediators’ levels in a cohort of Egyptian patients with diabetic macular oedema
Background: The aim was to study aqueous humour inflammatory mediators’ levels in a cohort of Egyptian patients with diabetic macular oedema (DMO). Methods: This was a case-control prospective study conducted on 2 groups: 25 eyes of 22 (11 females) patients seeking treatment for DMO as patients group, and 10 eyes of 10 (4 females) cataract patients as a control group. Aqueous humour was aspirated before intravitreal injection (patients’ group) or cataract surgery (control group). Inflammatory mediators in aqueous humour were measured using a multiplex bead immunoassay kit of 27 pre-mixed cytokines. Results: Eotaxin, interferon gamma-induced protein 10 (IP-10), monocyte chemoattractant protein-1 (MCP-1/CCL2) and interleukin-8 (IL-8/CXCL8) were found significantly higher in patients’ group compared to control group (p = 0.043, 0.037, 0.001, 0.015 respectively). On the contrary, interferon-gamma (IFN-gamma) and granulocyte colony-stimulating factor (G-CSF) were found significantly higher in control group than patients’ group (p = 0.003, 0.019 respectively). Basic fibroblast growth factor (Basic-FGF/FGF-2) and interleukin-1 receptor antagonist (IL-1ra) were found higher (but not statistically significant) in controls (p = 0.100 and 0.070 respectively). Additionally, a negative and significant correlation was found between Eotaxin level in aqueous humour and central macular thickness. Conclusions: Some mediators might be implicated in the pathogenesis of DMO either augmenting or suppressing role. Eotaxin, IP-10, MCP-1 and IL-8 might have a role in cases not responding to standard anti-vascular endothelial growth factor (VEGF) therapy. IL-1ra might have a protective role; therefore, the effectiveness of intravitreal injection of IL-1ra homologue needs to be studied in future clinical trials.
- Open Access
- 9 November 2023
- Published by Elsevier in The Breast
- Vol. 71, S44
PO88 INCREASED EXPRESSION OF METTL3 GENE IN A COHORT OF EGYPTIAN FEMALE PATIENTS WITH LOCALLY ADVANCED BREAST CANCER
- 9 November 2023
- Published by Elsevier in The Breast
- Vol. 71, S44
Open AccessPO88 INCREASED EXPRESSION OF METTL3 GENE IN A COHORT OF EGYPTIAN FEMALE PATIENTS WITH LOCALLY ADVANCED BREAST CANCER
- 1 December 2022
- Published by Allerton Press in Molecular Genetics, Microbiology and Virology
- Vol. 37 (4) , 242-247
Plasma Long Non-Coding RNA ZFAS1 as a Potential Diagnostic Biomarker for HCV-Related Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) represents the sixth most common cancer worldwide. Cirrhosis induced by hepatitis-C virus (HCV) infection is a key risk fact
- 1 December 2022
- Published by Allerton Press in Molecular Genetics, Microbiology and Virology
- Vol. 37 (4) , 242-247
Plasma Long Non-Coding RNA ZFAS1 as a Potential Diagnostic Biomarker for HCV-Related Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) represents the sixth most common cancer worldwide. Cirrhosis induced by hepatitis-C virus (HCV) infection is a key risk fact
- Open Access
- 3 March 2022
- Published by Springer Nature in Egyptian Rheumatology and Rehabilitation
- Vol. 49 (1) , 1-9
Role of global femoral cartilage in assessing severity of primary knee osteoarthritis
- 3 March 2022
- Published by Springer Nature in Egyptian Rheumatology and Rehabilitation
- Vol. 49 (1) , 1-9
Open AccessRole of global femoral cartilage in assessing severity of primary knee osteoarthritis
- 10 March 2019
- Published by Springer Nature
- Vol. 1959, 51-64
Protein Biomarker Discovery Using Human Blood Plasma Microparticles
Cells shed into the extracellular space a population of membranous vesicles of plasma membrane origin called microparticles (MP). Given the fact that MP are abundantly present in body fluids including plasma, rich in cell-type or disease-specific proteins and formed in conditions of stress and injury, they have been extensively investigated as biomarkers in various diseases. With the advancement in the mass spectrometry-based proteome analysis, the knowledge of the protein composition of plasma MP (PMP) has been intensively expanded, which aids the discovery of novel diagnostic target proteins. However, the lack of standardized and accurate protocols for PMP isolation limits the implementation of PMP as biomarkers in clinical settings. Here, we describe in detail a robust protocol for PMP isolation from human blood plasma via ultracentrifugation followed by label-free quantitative proteome analysis of PMP.
- 10 March 2019
- Published by Springer Nature
- Vol. 1959, 51-64
Protein Biomarker Discovery Using Human Blood Plasma Microparticles
Cells shed into the extracellular space a population of membranous vesicles of plasma membrane origin called microparticles (MP). Given the fact that MP are abundantly present in body fluids including plasma, rich in cell-type or disease-specific proteins and formed in conditions of stress and injury, they have been extensively investigated as biomarkers in various diseases. With the advancement in the mass spectrometry-based proteome analysis, the knowledge of the protein composition of plasma MP (PMP) has been intensively expanded, which aids the discovery of novel diagnostic target proteins. However, the lack of standardized and accurate protocols for PMP isolation limits the implementation of PMP as biomarkers in clinical settings. Here, we describe in detail a robust protocol for PMP isolation from human blood plasma via ultracentrifugation followed by label-free quantitative proteome analysis of PMP.
- 10 July 2017
- Published by Wiley in Proteomics – Clinical Applications
- Vol. 11 (11-12)
Quantitative proteome analysis of plasma microparticles for the characterization of HCV‐induced hepatic cirrhosis and hepatocellular carcinoma
Purpose: Hepatocellular carcinoma (HCC) is the most common primary malignant liver tumor and a leading cause of cancer‐related deaths worldwide. Cirrhosis induced by hepatitis‐C virus (HCV) infection is the most critical risk factor for HCC. However, the mechanism of HCV‐induced carcinogenesis is not fully understood. Plasma microparticles (PMP) contribute to numerous physiological and pathological processes and contain proteins whose composition correlates to the respective pathophysiological conditions.Experimental design: We analyzed PMP from 22 HCV‐induced cirrhosis patients, 16 HCV‐positive HCC patients with underlying cirrhosis and 18 healthy controls. PMP were isolated using ultracentrifugation and analyzed via label‐free LC‐MS/MS.Results: We identified 840 protein groups and quantified 507 proteins. 159 proteins were found differentially abundant between the three experimental groups. PMP in both disease entities displayed remarkable differences in the proteome composition compared to healthy controls. Conversely, the proteome difference between both diseases was minimal. GO analysis revealed that PMP isolated from both diseases were significantly enriched in proteins involved in complement activation, while endopeptidase activity was downregulated exclusively in HCC patients.Conclusion: This study reports for the first time a quantitative proteome analysis for PMP from patients with HCV‐induced cirrhosis and HCC. Data are available via ProteomeXchange with identifier PXD005777.
- 10 July 2017
- Published by Wiley in Proteomics – Clinical Applications
- Vol. 11 (11-12)
Quantitative proteome analysis of plasma microparticles for the characterization of HCV‐induced hepatic cirrhosis and hepatocellular carcinoma
Purpose: Hepatocellular carcinoma (HCC) is the most common primary malignant liver tumor and a leading cause of cancer‐related deaths worldwide. Cirrhosis induced by hepatitis‐C virus (HCV) infection is the most critical risk factor for HCC. However, the mechanism of HCV‐induced carcinogenesis is not fully understood. Plasma microparticles (PMP) contribute to numerous physiological and pathological processes and contain proteins whose composition correlates to the respective pathophysiological conditions.Experimental design: We analyzed PMP from 22 HCV‐induced cirrhosis patients, 16 HCV‐positive HCC patients with underlying cirrhosis and 18 healthy controls. PMP were isolated using ultracentrifugation and analyzed via label‐free LC‐MS/MS.Results: We identified 840 protein groups and quantified 507 proteins. 159 proteins were found differentially abundant between the three experimental groups. PMP in both disease entities displayed remarkable differences in the proteome composition compared to healthy controls. Conversely, the proteome difference between both diseases was minimal. GO analysis revealed that PMP isolated from both diseases were significantly enriched in proteins involved in complement activation, while endopeptidase activity was downregulated exclusively in HCC patients.Conclusion: This study reports for the first time a quantitative proteome analysis for PMP from patients with HCV‐induced cirrhosis and HCC. Data are available via ProteomeXchange with identifier PXD005777.